Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Chevalier JM, Hansen MA, Coskun E, Sy KTL, Drakes J, Dowling S, Williams A, Jenkins S, Amole C, Haimbe P, Mpasela F, Shakwelele H, Nichols BE. Cost-effectiveness of intervention combinations towards the elimination of vertical transmission of HIV in limited-resource settings: a mathematical modelling study. Lancet Glob Health. 2024 Mar; 12(3):e457-e466. PMID: 38365416.
-
Chevalier JM, Han AX, Hansen MA, Klock E, Pandithakoralage H, Ockhuisen T, Girdwood SJ, Lekodeba NA, de Nooy A, Khan S, Johnson CC, Sacks JA, Jenkins HE, Russell CA, Nichols BE. Impact and cost-effectiveness of SARS-CoV-2 self-testing strategies in schools: a multicountry modelling analysis. BMJ Open. 2024 Feb 27; 14(2):e078674. PMID: 38417953.
-
Rosen S, Blokhina E, Truong V, Bereznicka A, Gnatienko N, Quinn E, Lioznov D, Krupitsky E, Michals A, Lunze K, Samet JH. Comparative costs and potential affordability of a multifaceted intervention to improve treatment outcomes among people with HIV who inject drugs in Russia: economic evaluation of the LINC-II randomized controlled trial. J Int AIDS Soc. 2024 Feb; 27(2):e26208. PMID: 38403887.
-
Jain B, Rahim FO, Thirumala PD, McGarvey ML, Balzer J, Nogueira RG, van der Goes DN, de Havenon A, Sultan I, Ney J. Cost-benefit analysis of intraoperative neuromonitoring for cardiac surgery. J Stroke Cerebrovasc Dis. 2024 Mar; 33(3):107576. PMID: 38232584.
-
Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc. 2024 Jan 02; 13(1):e032413. PMID: 38156550.
-
Brooks MB, Pingali V, Nicholson T, Keshavjee S. Cost of inaction: a framework to estimate the economic cost of missing a patient with tuberculosis in the Indian context. BMJ Open. 2023 Dec 20; 13(12):e070717. PMID: 38128936.
-
Pelton SI, Mould-Quevedo JF, Nguyen VH. Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US. Expert Rev Vaccines. 2024; 23(1):82-87. PMID: 38093415.
-
Portnoy A, Pedersen K, Sy S, Tropé A, Engesaeter B, Kim JJ, Burger EA. Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis. Int J Cancer. 2024 Mar 15; 154(6):1073-1081. PMID: 38088449.
-
Brough J, Martinez L, Hatherill M, Zar HJ, Lo NC, Andrews JR. Public Health Impact and Cost-Effectiveness of Screening for Active Tuberculosis Disease or Infection Among Children in South Africa. Clin Infect Dis. 2023 Nov 30; 77(11):1544-1551. PMID: 37542465.
-
Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Assoumou SA. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Netw Open. 2023 Sep 05; 6(9):e2329583. PMID: 37703018.